Head-to-head evidence
ALLO-715 vs BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
ALLO-715
Developed by Allogene Therapeutics, Inc.
NCT04093596 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)
Developed by Chongqing Precision Biotech Co., Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04776330 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALLO-715's landscape · BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)'s landscape